Timothy C Dec Supernus Pharmaceuticals, Inc. (SUPN) insider trading activity

Timothy C Dec is Senior Vice-President & CFO of SUPERNUS PHARMACEUTICALS, INC.. Currently has a direct ownership of 1,246 shares of SUPN, which is worth approximately $56,070. The most recent transaction as insider was on Aug 22, 2025, when has been sold 11,780 shares (Common Stock) at a price of $44.49 per share, resulting in proceeds of $524,092. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.25K

0% 3M change

82.67% 12M change

Total Value Held $56,070

TIMOTHY C DEC Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Aug 22 2025	SELL Open market or private sale	$524,092 $44.49 p/Share	11,780 Reduced 90.43%	1,246 Common Stock
Mar 10 2025	SELL Payment of exercise price or tax liability	$64,665 $32.06 p/Share	2,017 Reduced 13.72%	12,681 Common Stock
Mar 10 2025	BUY Exercise of conversion of derivative security	-	3,800 Added 21.79%	13,636 Common Stock
Mar 05 2025	SELL Payment of exercise price or tax liability	$105,528 $33.05 p/Share	3,193 Reduced 22.66%	10,898 Common Stock
Feb 23 2025	BUY Grant, award, or other acquisition	-	2,500 Added 15.07%	14,091 Common Stock
Feb 22 2025	BUY Grant, award, or other acquisition	-	3,500 Added 23.19%	11,591 Common Stock
Feb 23 2024	SELL Payment of exercise price or tax liability	$38,184 $29.06 p/Share	1,314 Reduced 15.45%	7,190 Common Stock
Feb 23 2024	BUY Grant, award, or other acquisition	-	2,500 Added 22.72%	8,504 Common Stock
Feb 22 2024	BUY Grant, award, or other acquisition	-	500 Added 7.69%	6,004 Common Stock
Oct 13 2023	SELL Payment of exercise price or tax liability	$51,425 $26.91 p/Share	1,911 Reduced 27.3%	5,089 Common Stock
Oct 13 2023	BUY Exercise of conversion of derivative security	-	4,000 Added 36.36%	7,000 Common Stock
May 11 2023	SELL Payment of exercise price or tax liability	$25,857 $36.47 p/Share	709 Reduced 21.11%	2,650 Common Stock
May 11 2023	BUY Exercise of conversion of derivative security	-	1,500 Added 30.87%	3,359 Common Stock
Mar 14 2023	SELL Payment of exercise price or tax liability	$30,494 $38.65 p/Share	789 Reduced 27.77%	2,052 Common Stock
Mar 14 2023	BUY Exercise of conversion of derivative security	-	1,500 Added 34.55%	2,841 Common Stock
Feb 22 2023	BUY Grant, award, or other acquisition	-	500 Added 27.16%	1,341 Common Stock

Also insider at

OPGN

OPGEN INC Healthcare

Chief Financial Officer

TCD

Timothy C Dec

Senior Vice-President & CFO

Rockville, MD

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SUPN shares.

Notify only if

Value

Insider Trading

Get notified when an Supernus Pharmaceuticals, Inc. insider buys or sells SUPN shares.

Notify only if

Operation

Value

Type

News

Receive news related to SUPERNUS PHARMACEUTICALS, INC.

Track Activities on SUPN

Account